Positive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Rapid Onset and Sustained Efficacy: What Makes DT120 Stand Out?
A phase 3 trial of DT120 oral dissolving tablets has shown significant anxiety relief after a single dose in adults with generalized anxiety disorder. The study, conducted across multiple sites in the United States, enrolled 1,200 participants who met DSM‑5 criteria for GAD and had a baseline Hamilton Anxiety Rating Scale (HAM‑A) score of 20 or higher. Participants were randomly assigned to receive either a 100 µg dose, a 50 µg dose, or a placebo, and the primary endpoint was the change in HAM‑A score after 12 weeks.
The Panorama study demonstrated that both DT120 doses produced a rapid reduction in anxiety symptoms, with the 100 µg group showing a mean decrease of 12.3 points on the HAM‑A at week 12, compared to a 4.7‑point reduction in the placebo group. The 50 µg dose also outperformed placebo, achieving an 8.9‑point decline. These results suggest that a single oral dose can provide sustained relief over a three‑month period, potentially simplifying treatment regimens for patients who struggle with daily medication adherence. Researchers noted that the drug’s rapid onset—symptom improvement within 24 hours—could be particularly valuable for individuals experiencing acute anxiety episodes.
How Will This Influence Treatment Guidelines?
DT120 is a novel anxiolytic that dissolves quickly in the mouth, allowing the active compound to enter the bloodstream through the oral mucosa. This delivery method bypasses first‑pass metabolism, leading to higher bioavailability and a faster therapeutic effect. In the Panorama trial, participants reported noticeable relief within hours of taking the tablet, and the benefit persisted throughout the 12‑week follow‑up. The study also monitored safety, finding no serious adverse events and a low incidence of mild side effects such as dry mouth and transient dizziness. These safety data support the drug’s potential as a well‑tolerated option for patients who have limited tolerability to traditional oral anxiolytics.
The FDA’s preliminary review of the Panorama data indicates that the evidence may support approval of DT120 as a single‑dose therapy for GAD. If approved, clinicians could offer a treatment that reduces the burden of daily dosing, which is a common barrier to adherence in anxiety disorders. Moreover, the rapid onset may allow clinicians to manage acute anxiety crises more effectively, potentially decreasing emergency department visits. The company plans to submit a full application to the FDA in the coming months, and a larger post‑marketing study is being designed to evaluate long‑term outcomes and real‑world effectiveness.
What is the typical dosage of DT120 for adults with GAD? The Phase 3 trial used two doses: 100 µg and 50 µg. The 100 µg dose produced the most robust improvement, but the 50 µg dose also showed significant benefit over placebo.
Frequently Asked Questions
How quickly can patients expect relief after taking DT120? Participants reported noticeable symptom reduction within 24 hours, with the most pronounced improvement occurring in the first week of treatment.
Are there any notable side effects? The trial reported only mild, transient side effects such as dry mouth and dizziness. No serious adverse events were linked to the drug.